Date & Location
Saturday, April 29, 2017 7:30 AM - 3:05 PM
Ritz-Carlton, Washington, DC
Gastroenterology, Internal Medicine, Pediatrics, Radiology, Surgery - General
The incidence of inflammatory bowel disease (IBD) continues to rise in the world, and now affects more than 1.6 million Americans. We currently have a better understanding of the pathogenesis of IBD, allowing for the development of new therapies targeting the inflammatory pathways. Hence, the management of this complex disease is in turn becoming complex, where the clinician needs to use evidence-based medicine to personalize the use of the appropriate therapy for each individual patient. Becoming familiar with therapeutic drug monitoring and disease monitoring is essential in order to maximize the therapeutic benefit of drugs and the chance of maintaining IBD patients in remission and preventing complications. Patients with long standing IBD carry an increased risk of colon cancer, and the IBD therapies available have potential side effects. It is essential for healthcare providers to use current guidelines in prevention and screening of these complications in order to maximize patients’ health and the quality of care. IBD not only affects the gastrointestinal tract, but also several organ systems, often requiring a multidisciplinary approach to the patients involving several medicine specialties, colorectal surgery and radiology as well as nutrition support.
Other auto-immune and inflammatory diseases of the GI tract, such as eosinophilic esophagitis, celiac disease, microscopic colitis, auto-immune pancreatitis, appendicitis and diverticulitis, often present a challenge to the healthcare providers in terms of diagnosis, management and disease monitoring. New guidelines in the management of these diseases have been recently published, and need to be judiciously applied and individualized to patients.
The purpose of this symposium is to provide up-to-date information on the pathogenesis of the disease process, as well as evidence-based recommendations on the management and monitoring of IBD and other inflammatory and autoimmune disorders. Through this course, the gap between state of the art practice and current practices will be closed in order to provide a high quality, comprehensive, multidisciplinary approach to patients with IBD. We believe this approach will improve the quality of care provided to patients, decrease the risk of complications and morbidity, and reduce the overall burden of IBD on the patient and society.
This conference is intended for gastroenterologists, pathologists, pediatricians, radiologists, surgeons, internists, residents, nurse practitioners, registered nurses, physician assistants and healthcare practitioners interested in the treatment of IBD, inflammatory pathologies of the GI tract and state of the art endoscopic advances.
This program is endorsed by:
After completing this activity, the participant will be able to;
- Implement quality measures in IBD
- Utilize different biologics in treatment of IBD
- Examine the role of therapeutic drug monitoring in IBD and apply it in clinical practice
- Manage IBD in pregnancy
- Apply the new recommendations for the management of colon dysplasia in IBD
- Recognize and manage rheumatological complications in IBD
- Recognize and manage hepatobiliary complications in IBD
- Implement nutrition therapy and support in IBD
- Diagnose and manage primary sclerosing cholangitis and cholangiocarcinoma
- Apply a multidisciplinary approach when treating IBD and its complications
- Evaluate and treat eosinophilic esophagitis
- Diagnose and treat celiac disease and microscopic colitis
- Recognize and manage autoimmune pancreatitis
- Apply the new guidelines for the treatment of diverticulitis and appendicitis
Physician - $125
Resident/Fellow - $25
Advanced Practice Clinician - $75
Nurse - $75
Allied Health Professional - $75
All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at email@example.com or 202-780-1655.
Cancellations made in writing by March 17, 2017 will be subject to a 50% penalty. No refunds will be given after March 17, 2017. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, we will refund the registration fee, but are not responsible for any travel costs. Please call (202) 780-1655 or email MedStarCME@gmail.com if you have any questions or need any additional information.
1150 22nd Street, NW
Washington, DC 20037
Discounted valet parking is available for attendees at is $23 per day.
MedStar Georgetown University Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
MedStar Georgetown University Hospital designates this live activity for a maximum of 7 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. Nurses who attend a Category 1 CME certified activity can complete the continuing education hours section of the ANCC Professional Development Record in order to document the courses attended and the hours obtained.